🧫
experiment

In vitro T-cell killing assay with OVA-presenting tumor cells

🧫 Experiment Protocol ExploratorycancerNPM1OVA-presenting tumor cells and OT-1 transgenic T cellsproposed
Assessment of antigen-specific T-cell mediated killing of tumor cells presenting ovalbumin (OVA) by OT-1 transgenic T cells. This experiment evaluated how NPM1 deficiency affects the ability of tumor cells to present antigens and be recognized and killed by specific cytotoxic T lymphocytes. The study demonstrated that Npm1 deficiency increased MHC-I and MHC-II molecule expression and enhanced specific T-cell killing capacity.
PRIMARY OUTCOME
T-cell mediated tumor cell killing efficiency
EXPECTED OUTCOMES
NPM1 deficiency would enhance T-cell recognition and killing of tumor cells
SUCCESS CRITERIA
Increased cytotoxic T lymphocyte-mediated tumor cell death
PROTOCOL
In vitro co-culture of OVA-presenting tumor cells with OT-1 transgenic T cells to measure antigen-specific cytotoxicity
LINKED HYPOTHESES
Source: PMID 39402629 ↗
🧫 Experiment Extras
PATHWAY
antigen presentation pathway, MHC-I presentation
MARKET PRICE
$0.50
STATUS
proposed
Related Target
NPM1composite 0.513
View on SciDEX ↗